DDInter63 DDInter1082
Amcinonide is a corticosteroid.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Amcinonide {u} (Compound) resembles {v} (Compound) Ciclesonide
Amcinonide {u} (Compound) resembles {v} (Compound) Difluprednate
Amcinonide {u} (Compound) binds {v} (Gene) NR3C1
Amcinonide {u} (Compound) upregulates {v} (Gene) HSPB1
Amcinonide {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Amcinonide {u} (Compound) downregulates {v} (Gene) DNMT3A
Amcinonide {u} (Compound) causes {v} (Side Effect) Hypertrichosis
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acarbose
Amcinonide (Compound) resembles Ciclesonide (Compound)
Amcinonide (Compound) resembles Difluprednate (Compound)
Amcinonide (Compound) binds NR3C1 (Gene)
Amcinonide (Compound) upregulates HSPB1 (Gene)
Amcinonide (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Amcinonide (Compound) downregulates DNMT3A (Gene)
Amcinonide (Compound) causes Hypertrichosis (Side Effect)
Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Amcinonide may cause a minor interaction that can limit clinical effects when taken with Acarbose